ArticleClinical and translational medicine2022
FTO-mediated m
Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Critical roles of m6A demethylase FTO in ovarian aging.Biogerontology · 2026Review
- The translational potential of m6A RNA methylation in DKD: emerging biomarkers for early detection and targeted therapies.Frontiers in medicine · 2026Review
- SOCS1 improves abnormal IgA galactosylation in IgA nephropathy by regulating the TLR9/MyD88 pathway.Immunologic research · 2025Article
- m6A Ribonucleic Acid Methylation in Fibrotic Diseases of Visceral Organs.Small science · 2025Review
- The latest progression of N6-methyladenosine (mFrontiers in endocrinology · 2025Review
- WTAP-mediated mRedox report : communications in free radical research · 2024Article
- Electrochemical detection of FTO with NRSC advances · 2024Article
- NAging and disease · 2024Review
- Nucleic acid and protein methylation modification in renal diseases.Acta pharmacologica Sinica · 2024Review
- N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications.Frontiers in endocrinology · 2024Review
- FTO in health and disease.Frontiers in cell and developmental biology · 2024Review
- The role of N-methyladenosine modification in acute and chronic kidney diseases.Molecular medicine (Cambridge, Mass.) · 2023Review
- RNA sequencing reveals the mechanism of FTO in inhibiting inflammation and excessive proliferation of lipopolysaccharide-induced human glomerular mesangial cells.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms.Frontiers in pharmacology · 2023Article
- The role of mFrontiers in endocrinology · 2023Review
- FTO-mediated mClinical and translational medicine · 2022Article
- A bibliometric analysis of RNA methylation in diabetes mellitus and its complications from 2002 to 2022.Frontiers in endocrinology · 2022Review
- mKidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.